A two-year randomised trial published in the New England Journal of Medicine has found that weekly semaglutide, the active ingredient of Wegovy, reduced body-mass index by 13.5% in children aged six to eleven with obesity, while BMI rose in children given a placebo. Gastrointestinal side-effects were common and weight began to return when treatment stopped. No GLP-1 drug is approved for children this young, and the findings will intensify debate about drug treatment in childhood, including in India, where cheap generic semaglutide has been available since March.
Childhood obesity has proved stubbornly hard to treat. Lifestyle programmes help some children, but many regain weight, and obesity that begins in childhood tends to persist into adulthood. The STEP Young trial, presented at ObesityWeek in Maryland and published online in NEJM on 16 November, is the first large placebo-controlled test of a GLP-1 drug in primary-school-age children.
How the drug works
Semaglutide mimics GLP-1, a hormone released by the gut after eating. It acts on the brain’s appetite centres to increase fullness and reduce hunger, and it slows the emptying of the stomach. The result is that people eat less. Developed first for type 2 diabetes, it was approved for weight management in adults in 2021 and, in the United States, for adolescents aged twelve to seventeen in December 2022. Younger children had not been tested in a trial of this size.
What the trial did
STEP Young was a Phase III, double-blind trial funded by Novo Nordisk, which makes semaglutide. According to the report in Healio and Contemporary Pediatrics, it enrolled 167 children aged six to under twelve whose BMI was at or above the 95th percentile for their age and sex. Their average age was ten, and 59% were girls.
Children were randomised two to one: 112 received weekly semaglutide injections and 55 received placebo. Both groups had lifestyle counselling. The dose was built up to 2.4 mg for children over 60 kg, 1.7 mg for those between 45 and 60 kg, or the highest dose tolerated. Treatment lasted 104 weeks, followed by seven weeks off the drug. The first author is Ania Jastreboff of Yale University.
What it found
The primary measure was the percentage change in BMI at 68 weeks:
- BMI fell 13.5% on semaglutide and rose 2.7% on placebo, a difference of 16.2 percentage points.
- 78.7% of children on semaglutide cut BMI by at least 10%, against none on placebo.
- 38% of children on the drug fell below the 95th percentile, the clinical threshold for obesity, against 2% on placebo.
- Waist circumference, blood pressure, triglycerides and a marker of inflammation also improved.
- In a subgroup of 50 children whose body composition was measured by DXA scanning, the share of body weight that was fat fell by 4.7 percentage points on semaglutide against 1.1 on placebo, suggesting the loss was mainly fat rather than lean tissue.
At two years, BMI was 9.4% below baseline on semaglutide and 8.4% above on placebo. Note that the effect had partly waned between 68 and 104 weeks, and that BMI rose again during the seven-week washout. Children’s BMI naturally changes as they grow, which is why the placebo group’s rise matters as a comparison.
Novo Nordisk’s earlier topline announcement highlighted a larger figure, a 17.4% reduction. That figure assumes every child took the drug as intended; the 13.5% figure, the trial’s primary analysis, includes children who stopped or missed doses and is the more realistic estimate.
The side-effects
Almost all children in both groups had at least one adverse event. Gastrointestinal effects were much more common with semaglutide: vomiting in 70% against 29% on placebo, diarrhoea in 62% against 35%, and nausea in 58% against 24%, mostly mild or moderate and during dose increases. Serious adverse events occurred in 9% of each group, and 4% of children on semaglutide stopped because of side-effects. The researchers reported no effect on puberty or bone density. Antje Körner of the University of Leipzig, a commentator at the meeting, said: “Overall, we can reassure and conclude that there are no new safety concerns.”
A shift in thinking, with caveats
Daniel Hsia of Emory University, who was not involved, told Healio the results support “a paradigm shift moving away from watchful waiting to earlier treatment of obesity”. Martin Wabitsch of Ulm University, who presented the data, described childhood obesity as “a chronic relapsing disease”.
Several questions remain. A two-year trial cannot show what years of injections mean for a growing child, or whether children must stay on the drug indefinitely. The trial was funded by the manufacturer. Semaglutide is not approved in the United States for children under twelve, and guidance differs: the American Academy of Pediatrics allows drug treatment to be considered from age eight, while the WHO’s recent guidance, as reported by Healio, restricts it to older children who have not responded to lifestyle measures. NSH did not verify the WHO guidance at source.
The India angle
India’s patent on semaglutide expired in March 2026, and companies including Dr Reddy’s, Sun Pharma, Zydus, Alkem, Glenmark and Natco launched generics at a fraction of the original price, some for under ₹2,000 a month. That makes the drug far more accessible, and raises the risk of use outside approved indications. NSH found no evidence that any Indian generic is approved for children.
Childhood obesity in India is rising from a low base. UNICEF India, citing the National Family Health Survey 2019–21, reported that overweight among children under five rose to 3.4% from 1.5% fifteen years earlier, and projects more than 27 million Indians aged five to nineteen will have obesity by 2030. National surveys do not report figures for ages six to eleven, a data gap that matters if drug treatment is to be considered.
What to watch
- Whether Novo Nordisk seeks approval for children under twelve.
- Follow-up data after treatment stops.
- Any guidance from Indian paediatric bodies or the CDSCO on GLP-1 use in children.
– Aditya Raja



